ALOX12：贝伐珠单抗反应、免疫治疗效果和结直肠癌预后的新见解

数据集获取（Figshare）

• 源站标题：Table_1_ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer.xlsx
• DOI：10.3389/fimmu.2022.910582.s004
• 发布日期：2022-06-27
• 文件数：1 个
• 文件总体积：14.84 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_ALOX12_A_Novel_Insight_in_Bevacizumab_Response_Immunotherapy_Effect_and_Prognosis_of_Colorectal_Cancer_xlsx/20156006

命令行下载

curl -L -o "Table_1_ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer.xlsx" "https://ndownloader.figshare.com/files/36041696"

文件清单

• Table_1_ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer.xlsx（14.84 KB）

文件总体积 14.84 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Colorectal cancer is a highly malignant cancer with poor prognosis and mortality rates. As the first biological agent approved for metastatic colorectal cancer (mCRC), bevacizumab was confirmed to exhibit good performance when combined with chemotherapy and immunotherapy. However, the efficacy of both bevacizumab and immunotherapy is highly heterogeneous across CRC patients with different stages. Thus, exploring a novel biomarker to comprehensively assess the prognosis and bevacizumab and immunotherapy response of CRC is of great significance. In our study, weighted gene co-expression network analysis (WGCNA) and the receiver operating characteristic (ROC) curves were employed to identify bevacizumab-related genes. After verification in four public cohorts and our internal cohort, ALOX12 was identified as a key gene related to bevacizumab response. Prognostic analysis and in vitro experiments further demonstrated that ALOX12 was closely associated with the prognosis, tumor proliferation, invasion, and metastasis. Multi-omics data analysis based on mutation and copy number variation (CNV) revealed that RYR3 drove the expression of ALOX12 and the deletion of 17p12 inhibited ALOX12 expression, respectively. Moreover, we interrogated the relationship between ALOX12 and immune cells and checkpoints. The results exhibited that high ALOX12 expression predicted a higher immune infiltration and better immunotherapy response, which was further validated in Tumor Immune Dysfunction and Exclusion (TIDE) and Subclass Mapping (SubMap) methods. Above all, our study provides a stable biomarker for clinical protocol optimization, prognostic assessment, precise treatment, and individualized treatment of CRC.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2022.910582.s004（source: https://frontiersin.figshare.com/articles/dataset/Table_1_ALOX12_A_Novel_Insight_in_Bevacizumab_Response_Immunotherapy_Effect_and_Prognosis_of_Colorectal_Cancer_xlsx/20156006）。